Voya Investment Management LLC Has $11.85 Million Position in TG Therapeutics, Inc. $TGTX

Key Points

• Voya Investment Management LLC increased its stake in TG Therapeutics by 9.8%, owning 300,453 shares valued at approximately $11.8 million, indicating ongoing institutional interest in the biopharmaceutical company.
• Goldman Sachs upgraded TG Therapeutics to a "hold" rating with a target price of $37, while the stock currently has a Moderate Buy average rating among analysts.
• In its recent earnings report, TG Therapeutics missed EPS estimates, reporting $0.17 per share against an expectation of $0.32, despite a 92.1% increase in quarterly revenue year-over-year.

Voya Investment Management LLC boosted its holdings in shares of TG Therapeutics, Inc. (NASDAQ:TGTX - Free Report) by 9.8% in the 1st quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 300,453 shares of the biopharmaceutical company's stock after purchasing an additional 26,714 shares during the quarter. Voya Investment Management LLC owned about 0.19% of TG Therapeutics worth $11,847,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also recently bought and sold shares of TGTX. Goldman Sachs Group Inc. lifted its position in shares of TG Therapeutics by 21.9% during the 1st quarter. Goldman Sachs Group Inc. now owns 1,919,416 shares of the biopharmaceutical company's stock worth $75,683,000 after buying an additional 345,059 shares during the period. Wellington Management Group LLP lifted its position in shares of TG Therapeutics by 1,809.9% during the 1st quarter. Wellington Management Group LLP now owns 1,213,039 shares of the biopharmaceutical company's stock worth $47,830,000 after buying an additional 1,149,526 shares during the period. Invesco Ltd. lifted its position in shares of TG Therapeutics by 30.2% during the 1st quarter. Invesco Ltd. now owns 1,210,842 shares of the biopharmaceutical company's stock worth $47,744,000 after buying an additional 281,099 shares during the period. Principal Financial Group Inc. lifted its position in shares of TG Therapeutics by 1.3% during the 1st quarter. Principal Financial Group Inc. now owns 841,011 shares of the biopharmaceutical company's stock worth $33,161,000 after buying an additional 10,827 shares during the period. Finally, Driehaus Capital Management LLC bought a new position in shares of TG Therapeutics during the 1st quarter worth approximately $30,545,000. Institutional investors own 58.58% of the company's stock.

Insider Activity at TG Therapeutics

In other news, Director Sagar Lonial sold 20,852 shares of the business's stock in a transaction dated Thursday, September 11th. The stock was sold at an average price of $32.24, for a total value of $672,268.48. Following the sale, the director directly owned 94,061 shares in the company, valued at $3,032,526.64. The trade was a 18.15% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. 10.64% of the stock is currently owned by company insiders.

Analysts Set New Price Targets

Several equities analysts recently commented on the company. The Goldman Sachs Group upgraded TG Therapeutics to a "hold" rating and set a $37.00 target price for the company in a research report on Thursday, July 10th. B. Riley raised their price target on TG Therapeutics from $53.00 to $55.00 and gave the company a "buy" rating in a report on Wednesday. Four equities research analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the company's stock. Based on data from MarketBeat, TG Therapeutics has a consensus rating of "Moderate Buy" and an average price target of $48.00.

TG Therapeutics Trading Down 0.7%

Shares of NASDAQ TGTX traded down $0.24 during midday trading on Friday, hitting $32.37. The stock had a trading volume of 3,197,005 shares, compared to its average volume of 2,006,223. TG Therapeutics, Inc. has a fifty-two week low of $21.16 and a fifty-two week high of $46.48. The company has a debt-to-equity ratio of 0.89, a current ratio of 3.86 and a quick ratio of 2.96. The firm has a market cap of $5.14 billion, a P/E ratio of 87.49 and a beta of 1.88. The company's 50-day simple moving average is $31.91 and its 200 day simple moving average is $35.65.

TG Therapeutics (NASDAQ:TGTX - Get Free Report) last released its quarterly earnings data on Monday, August 4th. The biopharmaceutical company reported $0.17 EPS for the quarter, missing analysts' consensus estimates of $0.32 by ($0.15). TG Therapeutics had a net margin of 13.31% and a return on equity of 26.05%. The company had revenue of $141.15 million during the quarter, compared to the consensus estimate of $147.76 million. During the same quarter in the prior year, the company posted $0.04 EPS. The company's revenue for the quarter was up 92.1% compared to the same quarter last year. TG Therapeutics has set its FY 2025 guidance at EPS. Research analysts anticipate that TG Therapeutics, Inc. will post 0.08 EPS for the current year.

TG Therapeutics Company Profile

TG Therapeutics, Inc, a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.